http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-599714-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73ee0bacab5a7576a6a3244747f6ea99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b2d259c31f60b58a0d054d69d8ac69a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a6492bf3b8032568ab11d5036c2989e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15131c64e186364f7a27ba80aca71db3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c26a74ec6951ca4f2e89a72989f0149b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-26 |
| filingDate | 1945-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1948-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-599714-A |
| titleOfInvention | Manufacture of biguanide derivatives |
| abstract | Biguanide derivatives of the general formula <FORM:0599714/IV/1> wherein A represents an aryl radical which may bear one or more neutral or basic substituents, R represents an alkyl or p cycloalkyl radical and R1 hydrogen or an alkyl or cycloalkyl radical, or R and R1 form, with the adjacent nitrogen atom, a heterocyclic ring, X represents hydrogen or an alkyl or cycloalkyl radical, but either R1 or X is always hydrogen, and R11 represents hydrogen or an alkyl radical, are manufactured by the interaction of a substituted dicyandiamide <FORM:0599714/IV/2> with an arylamine ANHR11, e.g. by heating the substituted dicyandiamide with a salt of the arylamine in the presence of a solvent, e.g. water or b -ethoxyethanol. The products are useful as chemotherapeutic agents or intermediates therefor, those in which A is an aryl radical substituted by at least one halogen atom in m- or p-position to the nitrogen atom and in which R, R1 and X together contain more than one and fewer than 8 carbon atoms being particularly suitable as antimalarial agents. In examples, the following compounds, in most cases in the form of their hydrochlorides, are prepared from the appropriate dicyandiamide derivatives and the hydrochlorides of the appropriate arylamines: (N1-phenyl-, N1-o-, -m- and -p-chloro-, -p-bromo-, -2 5 -, -2 : 3-, -2 : 5-, -2 : 6-, and -3 : 4- and 3 : 5-dichloro-, -p-methylthiol-, -p-31 : 51-dimethylphenoxy-, -p-odo-, -4-chloro-2-methyl-, -3-chloro-4-methyl-, -4-chloro-3-methyl-, -p-fluoro-, -p-nitro-, -m-and -p-cyano-, -3-chloro-4-bromo-, -3-chloro-4-iodo- and -3 : 4 : 5-trichloro-phenyl-, N1-6-bromo - 2 - naphthyl-, N1 - p - phenetyl-, N1-(diphenyl-4)- and N1-o-, -m- and -p-tolyl-N5-isopropylbiguanide; N1-p-tolyl- and N1-p-bromophenyl-N5-ethylbiguanide; N1-p-chlorophenyl-N1 - methyl - N5 - isopropylbiguanide; N1-o-, -m- and -p-chloro-, -p-nitro-, -p-cyano- and -p-iodo - phenyl - N5 - methyl - N5 - isopropylbiguanide; N1 - p - chlorophenyl - N5 : N5-cyclopentamethylenebiguanide; N1-m- and -p-chlorophenyl-N5 : N5-diethylbiguanide; N4 : N5-di-isopropyl-, N4-ethyl-N5-isopropyl-N4 - n - proyl - N5 - isopropyl-, N4 : N5-di-, methyl-, N4-methyl-N5-ethyl-, N4-methyl-N5-n-, butyl-, N4 - isopropyl - N5 - cyclohexyl-, and N5 - isobutyl - H1 - p - chlorophenylbiguanide; and N1 - p - phenetyl - N4 - isopropyl - N5 - n - butylbiguanide. Additional starting materials specified are, on the one hand, N3-n-propyl-N3-methyl-N3-n-propyl-, N3-ethyl-N3-n- and -isopropyl-, N3-methyl-N3-n-, -sec.- and -iso-butyl-, N3-sec.- and -tert.-butyl-, N3-n-amyl-, N2-methyl-N3-n- and -iso-propyl-, N2-methyl-N3-n-, -iso-, -sec.- and -tert.-butyl- and N2-ethyl-N3-n-propyl-, -butyl- and -amyl-dicyandiamide; and, on the other hand, m-bromo-, m-iodo-, 3 : 4-dibromo-, 3 : 4-diiodo-, 3-chloro-4-fluoro-, 3 : 5-dichloro-4-bromo-, 3 : 5-dichloro-4-iodo-, 3-iodo-4-chloro-, 3-bromo-4-chloro-, 4-chloro-3-nitro-and 3-chloro-4-nitroaniline. Specifications 599,713 and 599,722 are referred to. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2941418-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3136816-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2742019-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2742019-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3272863-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9540325-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9884821-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110615886-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10252996-B2 |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.